NICE Launches ‘Concierge System’ To Guide Companies Through HTA Process
The health technology assessment body for England and Wales has launched an integrated, flexible advice portal to help guide companies through its potentially “bewildering” health system.
You may also be interested in...
NICE, the health technology assessment body for England and Wales, says its new proportionate approach to appraisals should be dynamic enough to “cope with the unique perspectives of new drugs” without being tailored to individual products or companies.
Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.
NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.